


What is recurrent non-muscle invasive bladder cancer?

Bladder cancer is the 6th most common cancer in the United States. In non-muscle invasive bladder cancer (NMIBC), the cancer is limited to the inner layers of the bladder. Frequently, this type of cancer returns, leaving patients with a difficult choice to make between treatment options.

Our study

Compared to other common cancers, there has been much less research on bladder cancer. As a result, there are many unanswered questions that make it difficult for patients and those who care for them to make decisions about their treatment. This study has the potential to answer some of these questions, ultimately helping to identify the right treatment, for the right patient, at the right time.



Layers of the Bladder

What do we know about treatment for recurrent NMIBC?

In this study, you and your doctor will choose your treatment option. One treatment for recurrent NMIBC is additional therapy with medicine such as Bacillus Calmette-Guerin (BCG), which is inserted directly into the bladder. The other option is to undergo a surgery called a cystectomy to remove your bladder.

Study goal

The goal of our study is to compare the outcomes of additional therapy with medicine versus bladder removal. We will be following those with NMIBC that has recurred or not responded to treatment over the course of up to four years. We hope to help future patients and those who care for them make better-informed decisions based on the preferences and the outcomes of patients like them.

We are inviting you to participate in this study. If you choose to participate, after you and your doctor select your treatment option we would collect data from you about your experiences during and after treatment.

Frequently Asked Questions

Will I get to select my treatment option?

The treatment option you choose is completely up to you and your doctor. It does not impact your ability to participate in our study.

What happens if I choose not to participate in the study?

Your participation is completely voluntary. Regardless of whether or not you choose to participate, your healthcare team will be here to support you through your treatment.

Date of IRB Approval: 08/06/2019

Institutional Review Board

What are the risks and benefits to each treatment option?

There is still much speculation around the risks and benefits of each treatment option. Choosing between additional therapy with medicine and removing the bladder is an incredibly difficult decision. This is why patients like you are needed to enroll in this study. By improving our understanding of who benefits most from each treatment, you can help future patients in this same challenging situation make their decision. Even more, you can assist their doctors, caregivers, and entire healthcare team in determining how best to support patients like yourself.

What type of data will be collected?

We will ask you to complete several surveys per year for up to four years and you will be compensated for your time. Patient partners have tested these surveys and found that they take up to 20 minutes to complete. Quality of life after treatment and the impact on an individual's finances are some examples of information that will be gathered.

In order to understand how your experience relates to outcomes from your treatment, we will also use your medical record to obtain information about your medical history, the treatment you selected, and the results of your treatment. A research coordinator will further discuss these details with you.

Have patients been involved in the development of this study?

This study is unique because doctors and patients collaborated to bring over a thousand bladder cancer patients together to identify the questions that were most important to patients. With patients as partners, we have designed this study to help answer the most important questions for bladder cancer patients like you.

We have additionally incorporated the voice of patients throughout the development of this study. We have a team of patients and caregivers who have agreed to continue to provide input into the study design and results.

Who is being included in this study?

It is important to us that this study represents all types of patients, including people of color and women. If you take part in this study, you will be helping people like you make decisions about their healthcare journeys, decisions that will be informed by the critical information you provide as part of this study.

What if I have more questions?

For more information about this study, please talk with your healthcare provider or contact our study representative: **(800) 972-4956 | (206) 616-6577 | cisto@uw.edu***

*We cannot guarantee the confidentiality of communication sent via email.

Date of IRB Approval: 08/06/2019

Institutional Review Board